Abstract:Background: Individuals with 22q11.2 Deletion Syndrome (22q11.2 DS) are a specific high-risk group for developing schizophrenia (SZ), schizoaffective disorder (SAD) and autism spectrum disorders (ASD). Several genes in the deleted region have been implicated in the development of SZ, e.g., PRODH and DGCR8. However, the mechanistic connection between these genes and the neuropsychiatric phenotype remains unclear. To elucidate the molecular consequences of 22q11.2 deletion in early neural development, we carried out RNA-seq analysis to investigate gene expression in early differentiating human neurons derived from induced pluripotent stem cells (iPSCs) of 22q11.2 DS SZ and SAD patients. Methods: Eight cases (ten iPSC-neuron samples in total including duplicate clones) and seven controls (nine in total including duplicate clones) were subjected to RNA sequencing. Using a systems level analysis, differentially expressed genes/gene-modules and pathway of interests were identified. Lastly, we related our findings from in vitro neuronal cultures to brain development by mapping differentially expressed genes to BrainSpan transcriptomes. Results: We observed ~2-fold reduction in expression of almost all genes in the 22q11.2 region in SZ (37 genes reached p-value < 0.05, 36 of which reached a false discovery rate < 0.05). Outside of the deleted region, 745 genes showed significant differences in expression between SZ and control neurons (p < 0.05). Function enrichment and network analysis of the differentially expressed genes uncovered converging evidence on abnormal expression in key functional pathways, such as apoptosis, cell cycle and survival, and MAPK signaling in the SZ and SAD samples. By leveraging transcriptome profiles of normal human brain tissues across human development into adulthood, we showed that the differentially expressed genes converge on a sub-network mediated by CDC45 and the cell cycle, which would be disrupted by the 22q11.2 deletion during embryonic brain development, and another sub-network modulated by PRODH, which could contribute to disruption of brain function during adolescence. Conclusions: This study has provided evidence for disruption of potential molecular events in SZ patient with 22q11.2 deletion and related our findings from in vitro neuronal cultures to functional perturbations that can occur during brain development in SZ.

Altered expression of mRNA profiles in blood of early-onset schizophrenia

Increased Variability Of Genomic Transcription In Schizophrenia

Transcriptomics Analysis Reveals Shared Pathways in Peripheral Blood Mononuclear Cells and Brain Tissues of Patients With Schizophrenia

Transcriptomic analysis of postmortem brain identifies dysregulated splicing events in novel candidate genes for schizophrenia.

Identification of differentially expressed genes of blood leukocytes for Schizophrenia

Integrated Transcriptome Analysis Reveals Novel Molecular Signatures for Schizophrenia Characterization.

Genome-Wide, Integrative Analysis Implicates Exosome-Derived MicroRNA Dysregulation in Schizophrenia.

Altered expression of the CSMD1 gene in the peripheral blood of schizophrenia patients

Exploring Transcription Factors-microRNAs Co-regulation Networks in Schizophrenia.

Identification of Potential Blood Biomarkers for Early Diagnosis of Schizophrenia Through RNA Sequencing Analysis

Integrative transcriptome network analysis of iPSC-derived neurons from schizophrenia and schizoaffective disorder patients with 22q11.2 deletion

Converging evidence implicates the abnormal microRNA system in schizophrenia.

Gene expression in patient-derived neural progenitors provide insights into neurodevelopmental aspects of schizophrenia

Whole transcriptome analysis reveals dysregulation of molecular networks in schizophrenia

A Co-Expression Network Analysis Reveals Lncrna Abnormalities in Peripheral Blood in Early-Onset Schizophrenia

Overdispersed Gene Expression in Schizophrenia

Expression of GSK3β, PICK1, NEFL, C4, NKCC1 and Synaptophysin in Peripheral Blood Mononuclear Cells of the First-Episode Schizophrenia Patients.

Two Gene Co-expression Modules Differentiate Psychotics and Controls

Overdispersed gene expression characterizes schizophrenic brains

Comprehensive profiling of small RNAs and their changes and linkages to mRNAs in schizophrenia and bipolar disorder

Identifying crucial biomarkers in peripheral blood of schizophrenia and screening therapeutic agents by comprehensive bioinformatics analysis